Reduce the acute adverse event of head and neck radiotherapy by an amino acid: prospective clinical trials

Reduce the acute adverse event of head and neck radiotherapy by an amino acid: prospective clinical trials - Reduce the acute adverse event of head and neck radiotherapy by an amino acid: prospective clinical trials

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024403

Enrollment

Registered

2016-10-14

Start date

2016-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head and neck cancer

Interventions

Abound (amino acid)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pathological type is head and neck cancer. 2) Will irradiation patients. 3) 18 years-old <=. 4) Performance status is 0-2. 5) The notice of the name of disease is accomplished and the person has ability for agreement.

Exclusion criteria

Exclusion criteria: 1) Irradiation history 2) After the treatment to other sites tumor for four weeks. 3) Infections 4) Serious complication 5) Cessation of radiation therapy 6) And so on

Design outcomes

Primary

Measure	Time frame
Dermatitis / mucositis (From beginning of an amino acid to four weeks after end of treatment.)	—

Countries

Japan

Contacts

Public ContactAtsushi Musha

Gunma university graduate school of medicine Radiation oncology

musha@gunma-u.ac.jp0272208378

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026